XT
NPCE icon

XTX Topco’s Neuropace NPCE Stock Holding History

XTX Topco’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$426K Sell
32,396
-1,579
-5% -$23.7K 0.01% 2185
2025
Q4 		$525K Buy
33,975
+22,983
+209% +$307K 0.01% 1550
2025
Q3 		$113K Buy
+10,992
New +$104K 0.01% 2001
2024
Q3 		– Sell
-24,055
Closed -$182K – 2431
2024
Q2 		$182K Buy
24,055
+8,643
+56% +$87.2K 0.02% 1275
2024
Q1 		$203K Buy
+15,412
New +$220K 0.03% 1161

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

XTX Topco's NPCE Position: Q1 2026 in Review

XTX Topco reduced its Neuropace (NPCE) stake by 4.6% in Q1 2026, selling an estimated $23.7K and leaving 32,396 shares worth $426K. The position accounts for 0.01% of the portfolio, ranked #2185.

XTX Topco first reported a position in NPCE in Q1 2024 and has held it in 5 quarters since. The position peaked at $525K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • XTX Topco held 32,396 shares of Neuropace worth $426K as of Q1 2026.
  • XTX Topco sold 1,579 Neuropace shares in Q1 2026, an estimated $23.7K.
  • Neuropace made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2185 holding.
  • XTX Topco first reported a position in Neuropace in Q1 2024 and has held it in 5 quarters since.
  • XTX Topco's Neuropace position peaked at $525K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.